All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 14-days deathsdetailed results ConPlas-19, 2020 0.56 [0.20; 1.57]
DAWN-Plasma, 2021 0.61 [0.24; 1.55]
NCT04397757, 2021 0.47 [0.04; 5.45]
Sekine (PLACOVID), 2021 2.14 [0.70; 6.58]
VERU-111, 2022 0.30 [0.14; 0.64]
0.62 [0.31 ; 1.24 ] ConPlas-19, 2020, DAWN-Plasma, 2021, NCT04397757, 2021, Sekine (PLACOVID), 2021, VERU-111, 2022 5 51% 1,222 moderate not evaluable death D28detailed results Abdulamir, 2021 1.00 [0.20; 5.12]
Abuhasira, 2021 0.72 [0.23; 2.24]
ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
AlQahtani, 2020 0.47 [0.04; 5.69]
Aman, 2021 0.51 [0.27; 0.96]
ASCOT, 2021 0.60 [0.06; 5.99]
Balcells, 2020 4.22 [0.33; 53.77]
Bennett-Guerrero, 2021 0.86 [0.24; 3.11]
CAN-COVID, 2020 0.67 [0.30; 1.50]
Co-CLARITY, 2021 0.92 [0.02; 50.28]
COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.12 [0.86; 1.46]
ConPlas-19, 2020 0.49 [0.20; 1.19]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
COPLA-II trial, 2020 1.17 [0.72; 1.92]
CORIMUNO-ANA-1, 2021 0.91 [0.38; 2.19]
CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.02 [0.62; 1.68]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Declercq J (COV-AID), 2021 1.02 [0.39; 2.66]
EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06]
EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72]
FACCT Trial, 2021 0.69 [0.28; 1.68]
Fragoso-Saavedra (PISCO), 2020 0.32 [0.13; 0.80]
Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.62 [0.33; 1.17]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36]
GS-US-540-5774, 10 days, 2020 0.77 [0.17; 3.50]
GS-US-540-5774, 5 days, 2020 0.52 [0.09; 2.86]
Gunst JD, 2021 0.99 [0.29; 3.42]
Horby, 2021 1.01 [0.93; 1.10]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
I-TECH (Lim), 2022 0.31 [0.09; 1.09]
ITAC, 2022 0.80 [0.42; 1.52]
Jamaati, 2021 1.19 [0.38; 3.72]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Kirenga, 2021 1.25 [0.46; 3.39]
Krolewiecki, 2020 0.49 [0.01; 26.05]
Lanzoni, 2021 0.14 [0.02; 0.96]
Li, 2020 0.59 [0.22; 1.59]
LIFESAVER, 2021 2.00 [0.16; 24.66]
Mahajan, 2021 1.23 [0.34; 4.42]
MARIPOSA, 2021 1.43 [0.42; 4.87]
Menichetti, 2021 0.75 [0.37; 1.53]
Metcovid, 2020 0.92 [0.67; 1.28]
Mobarak S (DISCOVER), 2021 1.10 [0.77; 1.57]
NCT04397757, 2021 0.15 [0.03; 0.75]
NCT04403477 (two doses), 2021 0.53 [0.14; 2.01]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31]
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88]
NCT04528368, 2021 0.88 [0.02; 50.20]
NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18]
NIH NIAID ACTT-1, 2020 0.73 [0.52; 1.03]
O’Donnell, 2021 0.47 [0.21; 1.06]
Pandit, 2021 0.95 [0.02; 50.33]
PC/COVID-19, 2021 0.63 [0.11; 3.58]
PERUCONPLASMA, 2021 0.36 [0.04; 3.13]
PlasmAr, 2020 0.93 [0.47; 1.85]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Raman, 2021 0.49 [0.02; 15.10]
RAPID (Sholzberg), 2021 0.22 [0.07; 0.67]
RECOVER, 2021 1.09 [0.38; 3.13]
RECOVERY, 2020 1.09 [0.97; 1.23]
RECOVERY, 2022 0.87 [0.77; 0.98]
RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04]
RECOVERY (AZI, Horby), 2020 0.97 [0.87; 1.08]
RECOVERY (colchicine), 2021 1.01 [0.93; 1.10]
RECOVERY (plasma), 2021 1.00 [0.93; 1.07]
RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rutgers, 2021 0.59 [0.33; 1.06]
Sakoulas, 2020 0.29 [0.03; 3.13]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shahbaznejad, 2020 2.21 [0.07; 67.87]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Shi, 2020 0.53 [0.01; 27.55]
Shu, 2020 0.38 [0.02; 8.14]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.56 [0.34; 7.13]
Tang X, 2020 0.98 [0.93; 1.02]
University of Minnesota, 2020 1.29 [0.51; 3.26]
Veiga, 2021 2.70 [0.92; 7.92]
Zhang, 2020 0.50 [0.17; 1.50]
0.92 [0.88 ; 0.96 ] Abdulamir, 2021, Abuhasira, 2021, ACTT-2 (Kalil), 2020, AlQahtani, 2020, Aman, 2021, ASCOT, 2021, Balcells, 2020, Bennett-Guerrero, 2021, CAN-COVID, 2020, Co-CLARITY, 2021, COALITION II Covid-19 Brazil (Furtado), 2020, COL-COVID (Pascual-Figal), 2021, COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CONTAIN COVID-19, 2021, COPLA-II trial, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, DAWN-Plasma, 2021, Declercq J (COV-AID), 2021, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, FACCT Trial, 2021, Fragoso-Saavedra (PISCO), 2020, Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, Horby, 2021, HYDRA (Hernandez-Cardenas), 2021, I-TECH (Lim), 2022, ITAC, 2022, Jamaati, 2021, Kalil (ACTT-3), 2021, Kirenga, 2021, Krolewiecki, 2020, Lanzoni, 2021, Li, 2020, LIFESAVER, 2021, Mahajan, 2021, MARIPOSA, 2021, Menichetti, 2021, Metcovid, 2020, Mobarak S (DISCOVER), 2021, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04412772 (ARCHITECTS), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04528368, 2021, NCT04577534 (COVIDSTORM), 0, NIH NIAID ACTT-1, 2020, O’Donnell, 2021, Pandit, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Raman, 2021, RAPID (Sholzberg), 2021, RECOVER, 2021, RECOVERY, 2020, RECOVERY, 2022, RECOVERY (Aspirin), 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, Rosas (REMDACTA), 2021, Rutgers, 2021, Sakoulas, 2020, Sekine (PLACOVID), 2021, Shahbaznejad, 2020, Shashi Bhushan, 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, SOLIDARITY (WHO study) HCQ, 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, STOP-COVID (Guimarães), 2021, Tabarsi, 2020, Talaschian, 2021, Tang X, 2020, University of Minnesota, 2020, Veiga, 2021, Zhang, 2020 93 24% 98,235 moderate critical death or transfer to ICUdetailed results BACC Bay Tocilizumab Trial, 2020 0.97 [0.50; 1.88]
Gunst JD, 2021 0.55 [0.26; 1.17]
Lopardo, 2021 0.65 [0.35; 1.22]
RAPID (Sholzberg), 2021 0.70 [0.44; 1.12]
RECOVERY, 2020 1.09 [0.99; 1.20]
0.84 [0.62 ; 1.13 ] BACC Bay Tocilizumab Trial, 2020, Gunst JD, 2021, Lopardo, 2021, RAPID (Sholzberg), 2021, RECOVERY, 2020 5 53% 5,989 moderate serious deathsdetailed results Abd-Elsalam, 2020 1.21 [0.36; 4.12]
Abdulamir, 2021 1.00 [0.20; 5.12]
ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
ACTIV-3/TICO LY-CoV555 , 2020 1.71 [0.56; 5.21]
ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
AlQahtani, 2020 0.47 [0.04; 5.69]
Aman, 2021 0.51 [0.27; 0.96]
ASCOT, 2021 0.60 [0.06; 5.99]
ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.88 [0.64; 1.20]
BACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62]
Balcells, 2020 3.26 [0.62; 17.12]
Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
CAN-COVID, 2020 0.67 [0.30; 1.50]
Cao, 2020 0.71 [0.36; 1.40]
Cao, 2020 0.15 [0.01; 3.29]
CAP-China (Wang et al.), 2020 1.10 [0.49; 2.45]
CAPE-COVID, 2020 0.45 [0.20; 1.02]
CAPSID, 2021 0.84 [0.28; 2.50]
CCAP-2, 2021 2.03 [0.61; 6.77]
Chen, 2020 0.56 [0.01; 30.20]
Co-CLARITY, 2021 0.92 [0.02; 50.28]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.47 [0.48; 4.52]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.43 [0.13; 1.44]
COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
COALIZAO ACTION, 2021 1.55 [0.90; 2.70]
CODEX (Tomazini), 2020 0.97 [0.72; 1.31]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.02 [0.77; 1.36]
ConCOVID (Gharbharan et al.), 2020 0.95 [0.20; 4.59]
CONFIDENT, 2020 0.84 [0.52; 1.37]
ConPlas-19, 2020 0.46 [0.19; 1.15]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
COP-COVID-19, 2021 0.96 [0.36; 2.56]
COPLA-II trial, 2020 1.17 [0.72; 1.92]
CORIMUNO-ANA-1, 2021 0.97 [0.46; 2.04]
CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51]
CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
COVID-PACT, 2022 0.91 [0.56; 1.48]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
Dabbous HM, 2020 0.51 [0.02; 15.41]
Darazam, 2021 1.21 [0.65; 2.25]
Darazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25]
Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Declercq J (COV-AID), 2021 1.02 [0.39; 2.66]
DEXA-COVID19, 2020 2.00 [0.21; 18.87]
EMPACTA, 2020 1.13 [0.54; 2.40]
Entrenas (Pilot Calcifediol), 2020 0.12 [0.01; 2.79]
EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06]
EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72]
FACCT Trial, 2021 0.96 [0.44; 2.08]
Fragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79]
Fu, 2020 1.00 [0.02; 51.66]
Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.62 [0.33; 1.17]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.81 [0.48; 1.36]
Galan, 2021 0.94 [0.51; 1.73]
Gonzalez (HCQ), 2020 0.33 [0.06; 1.78]
Gonzalez (IVER), 2020 0.83 [0.23; 3.02]
GRECCO-19, 2020 0.21 [0.02; 1.97]
GS-US-540-5773 (Goldman), 2020 0.73 [0.37; 1.44]
GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
Gunst JD, 2021 0.70 [0.20; 2.49]
HAHPS, 2020 7.00 [0.80; 60.90]
Hashim A, 2020 0.48 [0.11; 1.99]
Holm K, 2021 0.49 [0.08; 2.89]
Horby, 2021 1.01 [0.93; 1.10]
Hung et al., 2020 0.47 [0.01; 24.30]
HYCOVID, 2020 0.54 [0.21; 1.40]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
I-TECH (Lim), 2022 0.31 [0.09; 1.09]
INSPIRATION, 2021 1.09 [0.78; 1.53]
ITAC, 2022 0.80 [0.42; 1.52]
Jamaati, 2021 1.19 [0.38; 3.72]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Khamis, 2020 0.83 [0.23; 2.96]
Kirenga, 2021 1.25 [0.46; 3.39]
Kirti, 2021 0.12 [0.01; 2.36]
Krolewiecki, 2020 0.49 [0.01; 26.05]
Lanzoni, 2021 0.11 [0.01; 0.93]
Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12]
Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50]
Li, 2020 0.59 [0.22; 1.59]
Li, 2021 1.04 [0.02; 53.73]
Libster, 2020 0.50 [0.09; 2.71]
LIFESAVER, 2021 2.00 [0.16; 24.66]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
Lopardo, 2021 0.57 [0.24; 1.37]
Lopes (BRACE CORONA), 2021 0.97 [0.38; 2.50]
Lou (FAVIPIRAVIR), 2020 1.12 [0.02; 62.74]
Lou Y, 2020 1.00 [0.02; 55.80]
Mahajan, 2021 1.23 [0.34; 4.42]
Menichetti, 2021 0.75 [0.37; 1.53]
Metcovid, 2020 0.92 [0.67; 1.28]
Mobarak S (DISCOVER), 2021 1.15 [0.80; 1.67]
Murai, 2020 1.53 [0.53; 4.43]
NCT04385199, 2021 0.75 [0.15; 3.77]
NCT04397757, 2021 0.15 [0.03; 0.75]
NCT04403477 (two doses), 2021 0.53 [0.14; 2.01]
NCT04412772 (ARCHITECTS), 0 0.18 [0.01; 3.72]
NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31]
NCT04442191, 2021 0.11 [0.00; 143.68]
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88]
NCT04523831 (Mahmud), 2020 0.16 [0.01; 3.25]
NCT04528368, 2021 0.88 [0.02; 50.20]
NCT04542694, 2020 1.00 [0.02; 50.90]
NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18]
NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84]
NO COVID-19 (Lyngbakken), 2020 0.96 [0.06; 15.78]
Nojomi, 2020 0.49 [0.04; 5.58]
Nojomi, 2020 2.04 [0.18; 23.27]
NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20]
Nouri-Vaskeh, 2021 0.35 [0.06; 1.91]
ORCHID, 2020 1.07 [0.54; 2.11]
O’Donnell, 2021 0.47 [0.21; 1.06]
Pandit, 2021 0.95 [0.02; 50.33]
PC/COVID-19, 2021 0.63 [0.11; 3.58]
PERUCONPLASMA, 2021 0.36 [0.04; 3.13]
PlasmAr, 2020 0.93 [0.47; 1.85]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
ProPAC-COVID, 2021 0.08 [0.00; 8.65]
Rahmani, 2020 0.29 [0.05; 1.56]
Raman, 2021 0.49 [0.02; 15.10]
Ranjbar, 2021 0.40 [0.15; 1.08]
RAPID (Sholzberg), 2021 0.22 [0.07; 0.67]
Rasheed, 2020 0.13 [0.01; 1.09]
RCT-TCZ-COVID-19, 2021 2.24 [0.20; 25.37]
RECOVER, 2021 1.09 [0.38; 3.13]
RECOVERY, 2020 1.09 [0.97; 1.23]
RECOVERY, 2020 1.03 [0.91; 1.17]
RECOVERY, 2021 0.85 [0.76; 0.95]
RECOVERY, 2022 0.87 [0.77; 0.98]
RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04]
RECOVERY (AZI, Horby), 2020 0.97 [0.87; 1.08]
RECOVERY (colchicine), 2021 1.01 [0.93; 1.10]
RECOVERY (plasma), 2021 1.00 [0.93; 1.07]
RECOVERY (REGN-COV2), 2021 0.80 [0.70; 0.91]
RECOVERY dexamethasone, 2020 0.83 [0.75; 0.92]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93]
REMAP-CAP (plasma), 2021 0.96 [0.80; 1.15]
REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95]
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.08 [0.85; 1.38]
Ren, 2020 1.00 [0.02; 55.80]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rutgers, 2021 0.62 [0.36; 1.07]
Sadeghi , 2020 0.56 [0.12; 2.56]
Sakoulas, 2020 0.29 [0.03; 3.13]
Salehzadeh, 2020 1.00 [0.02; 51.41]
SAVE-MORE, 2021 0.45 [0.20; 0.99]
Sekhavati, 2020 0.49 [0.02; 14.80]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Shi, 2020 0.53 [0.01; 27.55]
Shu, 2020 0.38 [0.02; 8.14]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
Soin AS (COVINTOC), 2021 0.67 [0.29; 1.55]
Solaymani-Dodaran, 2021 1.22 [0.66; 2.26]
SOLIDARITY (interferon), 2020 1.16 [0.96; 1.40]
SOLIDARITY (lopi/rito), 2020 1.00 [0.79; 1.26]
SOLIDARITY (remdesivir), 2020 0.95 [0.81; 1.11]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
Steroids-SARI, 2020 0.91 [0.29; 2.86]
STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62]
Synairgen SG016, 2020 0.16 [0.01; 3.31]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.25 [0.30; 5.14]
Tang X, 2020 0.98 [0.93; 1.02]
TEACH, 2020 1.07 [0.34; 3.37]
Udwadia, 2020 0.50 [0.02; 15.03]
University of Minnesota, 2020 0.68 [0.11; 4.16]
Veiga, 2021 2.70 [0.92; 7.92]
Wang, 2020 1.00 [0.02; 52.54]
Yakoot, 2020 0.38 [0.07; 2.08]
Zhang, 2020 0.50 [0.17; 1.50]
0.91 [0.88 ; 0.95 ] Abd-Elsalam, 2020, Abdulamir, 2021, ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ACTT-2 (Kalil), 2020, AlQahtani, 2020, Aman, 2021, ASCOT, 2021, ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, BACC Bay Tocilizumab Trial, 2020, Balcells, 2020, Baldeon, 2022, Bennett-Guerrero, 2021, CAN-COVID, 2020, Cao, 2020, Cao, 2020, CAP-China (Wang et al.), 2020, CAPE-COVID, 2020, CAPSID, 2021, CCAP-2, 2021, Chen, 2020, Co-CLARITY, 2021, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, COALIZAO ACTION, 2021, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, COLCOVID, 2021, CONCOR-1, 2021, ConCOVID (Gharbharan et al.), 2020, CONFIDENT, 2020, ConPlas-19, 2020, CONTAIN COVID-19, 2021, COP-COVID-19, 2021, COPLA-II trial, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, COVID-PACT, 2022, CP-COVID-19, 2021, Dabbous HM, 2020, Darazam, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, DAWN-Plasma, 2021, Declercq J (COV-AID), 2021, DEXA-COVID19, 2020, EMPACTA, 2020, Entrenas (Pilot Calcifediol), 2020, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, FACCT Trial, 2021, Fragoso-Saavedra (PISCO), 2020, Fu, 2020, Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, Galan, 2021, Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, GRECCO-19, 2020, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, HAHPS, 2020, Hashim A, 2020, Holm K, 2021, Horby, 2021, Hung et al., 2020, HYCOVID, 2020, HYDRA (Hernandez-Cardenas), 2021, I-TECH (Lim), 2022, INSPIRATION, 2021, ITAC, 2022, Jamaati, 2021, Kalil (ACTT-3), 2021, Khamis, 2020, Kirenga, 2021, Kirti, 2021, Krolewiecki, 2020, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Li, 2020, Li, 2021, Libster, 2020, LIFESAVER, 2021, LIVE-AIR (Temesgen), 2021, Lopardo, 2021, Lopes (BRACE CORONA), 2021, Lou (FAVIPIRAVIR), 2020, Lou Y, 2020, Mahajan, 2021, Menichetti, 2021, Metcovid, 2020, Mobarak S (DISCOVER), 2021, Murai, 2020, NCT04385199, 2021, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04412772 (ARCHITECTS), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04442191, 2021, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04523831 (Mahmud), 2020, NCT04528368, 2021, NCT04542694, 2020, NCT04577534 (COVIDSTORM), 0, NIH NIAID ACTT-1, 2020, NO COVID-19 (Lyngbakken), 2020, Nojomi, 2020, Nojomi, 2020, NOR-Solidarity (hydroxychloroquine), 2021, Nouri-Vaskeh, 2021, ORCHID, 2020, O’Donnell, 2021, Pandit, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, PlasmAr, 2020, Pouladzadeh, 2021, ProPAC-COVID, 2021, Rahmani, 2020, Raman, 2021, Ranjbar, 2021, RAPID (Sholzberg), 2021, Rasheed, 2020, RCT-TCZ-COVID-19, 2021, RECOVER, 2021, RECOVERY, 2020, RECOVERY, 2020, RECOVERY, 2021, RECOVERY, 2022, RECOVERY (Aspirin), 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (plasma), 2021, REMAP-CAP (tocilizumab), 2021, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021, Ren, 2020, Rosas (REMDACTA), 2021, Rutgers, 2021, Sadeghi , 2020, Sakoulas, 2020, Salehzadeh, 2020, SAVE-MORE, 2021, Sekhavati, 2020, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 2021, Solaymani-Dodaran, 2021, SOLIDARITY (interferon), 2020, SOLIDARITY (lopi/rito), 2020, SOLIDARITY (remdesivir), 2020, SOLIDARITY (WHO study) HCQ, 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Steroids-SARI, 2020, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Tabarsi, 2020, Talaschian, 2021, Tang X, 2020, TEACH, 2020, Udwadia, 2020, University of Minnesota, 2020, Veiga, 2021, Wang, 2020, Yakoot, 2020, Zhang, 2020 185 16% 149,102 moderate critical deaths (time to event analysis only)detailed results ACTIV-3/ TICO (sotrovimab), 2021 1.02 [0.48; 2.17]
ACTIV-3/TICO (tixa), 2022 0.70 [0.50; 0.97]
ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
Balcells, 2020 3.26 [0.62; 17.12]
Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24]
COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
COLCOVID, 2021 0.88 [0.70; 1.11]
CONCOR-1, 2021 1.02 [0.77; 1.36]
ConPlas-19, 2020 0.46 [0.19; 1.15]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Fragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79]
Galan, 2021 0.94 [0.51; 1.73]
GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
Gunst JD, 2021 0.70 [0.20; 2.49]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Lanzoni, 2021 0.11 [0.01; 0.93]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84]
NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20]
PlasmAr, 2020 0.93 [0.47; 1.85]
RECOVERY, 2020 1.09 [0.97; 1.23]
RECOVERY (Aspirin), 2022 0.96 [0.89; 1.04]
RECOVERY (AZI, Horby), 2020 0.97 [0.87; 1.08]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Rutgers, 2021 0.62 [0.36; 1.07]
SOLIDARITY (remdesivir), 2020 0.95 [0.81; 1.11]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
Talaschian, 2021 1.25 [0.30; 5.14]
Zhang, 2020 0.50 [0.17; 1.50]
0.89 [0.82 ; 0.96 ] ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO (tixa), 2022, ACTT-2 (Kalil), 2020, Balcells, 2020, Baldeon, 2022, Bennett-Guerrero, 2021, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION II Covid-19 Brazil (Furtado), 2020, COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, COV-BARRIER, 2021, COVACTA (Rosas), 2020, CP-COVID-19, 2021, DAWN-Plasma, 2021, Fragoso-Saavedra (PISCO), 2020, Galan, 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, HYDRA (Hernandez-Cardenas), 2021, Kalil (ACTT-3), 2021, Lanzoni, 2021, LIVE-AIR (Temesgen), 2021, NIH NIAID ACTT-1, 2020, NOR-Solidarity (hydroxychloroquine), 2021, PlasmAr, 2020, RECOVERY, 2020, RECOVERY (Aspirin), 2022, RECOVERY (AZI, Horby), 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, Rosas (REMDACTA), 2021, Rutgers, 2021, SOLIDARITY (remdesivir), 2020, SOLIDARITY (WHO study) HCQ, 2020, Talaschian, 2021, Zhang, 2020 38 41% 50,349 moderate critical clinical deteriorationdetailed results BACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09]
Balcells, 2020 1.46 [0.44; 4.81]
Cao, 2020 0.11 [0.01; 2.21]
CAP-China (Wang et al.), 2020 0.95 [0.55; 1.64]
CAPSID, 2021 0.63 [0.29; 1.40]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.99 [0.57; 1.72]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.21 [0.69; 2.12]
COALIZAO ACTION, 2021 1.35 [0.85; 2.15]
CODEX (Tomazini), 2020 0.66 [0.43; 1.02]
COL-COVID (Pascual-Figal), 2021 0.38 [0.09; 1.58]
ConPlas-19, 2020 1.00 [0.65; 1.53]
CONTAIN COVID-19, 2021 0.94 [0.75; 1.18]
CORIMUNO-ANA-1, 2021 0.89 [0.42; 1.92]
CORIMUNO-SARI-1 (non ICU), 2021 1.01 [0.48; 2.12]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20]
COV-BARRIER, 2021 1.12 [0.58; 2.16]
ELACOI (lopinavir/ritonavir), 2020 3.69 [0.37; 36.57]
ELACOI (Standard of care), 2020 0.86 [0.06; 11.36]
EMPACTA, 2020 0.55 [0.33; 0.92]
GRECCO-19, 2020 0.11 [0.01; 1.08]
HAHPS, 2020 1.07 [0.63; 1.82]
Hashim A, 2020 0.40 [0.10; 1.63]
I-TECH (Lim), 2022 1.25 [0.87; 1.80]
Kirenga, 2021 0.91 [0.38; 2.17]
Li, 2021 0.52 [0.02; 15.78]
Li T, 2020 0.48 [0.01; 27.44]
Libster, 2020 0.52 [0.29; 0.94]
NCT04523831 (Mahmud), 2020 0.44 [0.23; 0.84]
RAPID (Sholzberg), 2021 0.69 [0.43; 1.10]
Ravichandran, 2021 0.02 [0.00; 0.36]
RCT-TCZ-COVID-19, 2021 1.05 [0.59; 1.86]
SAVE-MORE, 2021 0.36 [0.26; 0.50]
Shu, 2020 0.27 [0.01; 5.58]
Soin AS (COVINTOC), 2021 0.67 [0.26; 1.77]
STOP-COVID (Guimarães), 2021 0.54 [0.27; 1.07]
Synairgen SG016, 2020 0.50 [0.18; 1.38]
Tang X, 2020 1.00 [0.13; 7.45]
TEACH, 2020 1.80 [0.62; 5.21]
Wang, 2020 1.00 [0.02; 52.54]
Zhang, 2020 0.40 [0.10; 1.65]
0.79 [0.67 ; 0.92 ] BACC Bay Tocilizumab Trial, 2020, Balcells, 2020, Cao, 2020, CAP-China (Wang et al.), 2020, CAPSID, 2021, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALIZAO ACTION, 2021, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, ConPlas-19, 2020, CONTAIN COVID-19, 2021, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, COV-BARRIER, 2021, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, EMPACTA, 2020, GRECCO-19, 2020, HAHPS, 2020, Hashim A, 2020, I-TECH (Lim), 2022, Kirenga, 2021, Li, 2021, Li T, 2020, Libster, 2020, NCT04523831 (Mahmud), 2020, RAPID (Sholzberg), 2021, Ravichandran, 2021, RCT-TCZ-COVID-19, 2021, SAVE-MORE, 2021, Shu, 2020, Soin AS (COVINTOC), 2021, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Tang X, 2020, TEACH, 2020, Wang, 2020, Zhang, 2020 40 48% 8,339 moderate low clinical improvementdetailed results ACTIV-3/TICO (tixa), 2022 1.08 [0.97; 1.20]
ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33]
AVIFAVIR, 2020 0.53 [0.13; 2.19]
BACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41]
Balcells, 2020 0.91 [0.52; 1.60]
Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
CAN-COVID, 2020 1.39 [0.76; 2.54]
Cao, 2020 1.67 [0.84; 3.33]
Cao, 2020 1.31 [0.94; 1.83]
CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
CAPSID, 2021 1.58 [0.71; 3.49]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.81 [0.54; 1.22]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43]
COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07]
ConPlas-19, 2020 0.95 [0.60; 1.52]
COV-BARRIER, 2021 1.25 [1.04; 1.50]
COV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Darazam, 2021 1.37 [0.88; 2.13]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Dongsheng Wang, 2020 2.37 [0.40; 13.96]
EMPACTA, 2020 1.15 [0.90; 1.47]
Ghandehari, 2020 1.31 [1.00; 1.71]
GS-US-540-5773 (Goldman), 2020 0.79 [0.61; 1.02]
GS-US-540-5774, 10 days, 2020 1.16 [0.77; 1.74]
GS-US-540-5774, 5 days, 2020 1.65 [1.09; 2.49]
Gunst JD, 2021 1.14 [0.83; 1.57]
Huang, 2020 1.37 [0.73; 2.56]
Hung et al., 2020 3.92 [1.66; 9.24]
ITAC, 2022 1.06 [0.77; 1.45]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Li, 2020 1.40 [0.79; 2.49]
Li, 2021 1.76 [1.10; 2.81]
Lopardo, 2021 1.61 [0.75; 3.49]
Lou (FAVIPIRAVIR), 2020 1.25 [0.21; 7.62]
NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
NCT04542694, 2020 2.10 [1.04; 4.24]
NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49]
ORCHID, 2020 1.02 [0.73; 1.42]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 0.81 [0.50; 1.31]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06]
REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15]
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 0.83 [0.67; 1.03]
Ruzhentsova T, 2020 1.63 [1.14; 2.34]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
Shu, 2020 10.27 [1.17; 90.18]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
Synairgen SG016, 2020 2.32 [1.07; 5.04]
Tang X, 2020 1.04 [0.67; 1.62]
Udwadia, 2020 1.75 [1.10; 2.79]
1.17 [1.09 ; 1.26 ] ACTIV-3/TICO (tixa), 2022, ACTIV-3/TICO LY-CoV555 , 2020, ACTT-2 (Kalil), 2020, AVIFAVIR, 2020, BACC Bay Tocilizumab Trial, 2020, Balcells, 2020, Bennett-Guerrero, 2021, CAN-COVID, 2020, Cao, 2020, Cao, 2020, CAP-China (Wang et al.), 2020, CAPSID, 2021, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, ConPlas-19, 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Darazam, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Dongsheng Wang, 2020, EMPACTA, 2020, Ghandehari, 2020, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, Huang, 2020, Hung et al., 2020, ITAC, 2022, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Li, 2020, Li, 2021, Lopardo, 2021, Lou (FAVIPIRAVIR), 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, PlasmAr, 2020, Pouladzadeh, 2021, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (tocilizumab), 2021, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021, Ruzhentsova T, 2020, Sekine (PLACOVID), 2021, Shashi Bhushan, 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Synairgen SG016, 2020, Tang X, 2020, Udwadia, 2020 56 52% 17,334 moderate critical clinical improvement (14-day)detailed results ACTT-2 (Kalil), 2020 1.30 [1.03; 1.64]
AVIFAVIR, 2020 0.53 [0.13; 2.19]
Cao, 2020 2.00 [0.58; 6.94]
Cao, 2020 1.94 [1.09; 3.48]
CAP-China (Wang et al.), 2020 1.21 [0.64; 2.28]
Chen, 2020 0.56 [0.13; 2.48]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.01 [0.58; 1.76]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.83 [0.47; 1.44]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43]
COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07]
COV-BARRIER, 2021 1.28 [1.05; 1.56]
COV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09]
GS-US-540-5773 (Goldman), 2020 1.53 [1.02; 2.29]
GS-US-540-5774, 10 days, 2020 1.58 [1.01; 2.47]
GS-US-540-5774, 5 days, 2020 1.56 [1.00; 2.44]
Huang, 2020 1.37 [0.73; 2.56]
Kalil (ACTT-3), 2021 1.01 [0.79; 1.29]
Li, 2020 2.27 [0.90; 5.72]
Li, 2021 2.86 [1.24; 6.62]
Lou (FAVIPIRAVIR), 2020 1.25 [0.21; 7.62]
Lou Y, 2020 1.50 [0.26; 8.82]
ORCHID, 2020 1.02 [0.73; 1.42]
Pandit, 2021 8.77 [0.94; 81.67]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.85 [0.64; 1.12]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06]
Ruzhentsova T, 2020 1.28 [1.05; 1.56]
Sadeghi , 2020 3.63 [1.02; 12.93]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
Shu, 2020 10.27 [1.17; 90.18]
Tang X, 2020 1.33 [0.57; 3.11]
1.20 [1.05 ; 1.36 ] ACTT-2 (Kalil), 2020, AVIFAVIR, 2020, Cao, 2020, Cao, 2020, CAP-China (Wang et al.), 2020, Chen, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Huang, 2020, Kalil (ACTT-3), 2021, Li, 2020, Li, 2021, Lou (FAVIPIRAVIR), 2020, Lou Y, 2020, ORCHID, 2020, Pandit, 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, Ruzhentsova T, 2020, Sadeghi , 2020, Shashi Bhushan, 2021, Shu, 2020, Tang X, 2020 30 47% 9,428 moderate low clinical improvement (21-day)detailed results Cao, 2020 1.50 [0.22; 10.08]
Li T, 2020 2.09 [0.04; 119.96]
1.59 [0.28 ; 8.93 ] Cao, 2020, Li T, 2020 2 0% 59 moderate not evaluable clinical improvement (28-day)detailed results Abuhasira, 2021 1.70 [0.52; 5.49]
ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.27 [1.03; 1.57]
Bennett-Guerrero, 2021 1.02 [0.25; 4.20]
Cao, 2020 1.59 [0.84; 3.03]
CAP-China (Wang et al.), 2020 1.37 [0.79; 2.39]
COALITION II Covid-19 Brazil (Furtado), 2020 0.70 [0.47; 1.04]
COV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81]
COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
GS-US-540-5774, 10 days, 2020 1.88 [1.03; 3.42]
GS-US-540-5774, 5 days, 2020 1.75 [0.97; 3.17]
Li, 2020 1.42 [0.65; 3.10]
Li, 2021 4.26 [1.10; 16.44]
NIH NIAID ACTT-1, 2020 1.35 [1.03; 1.76]
ORCHID, 2020 0.97 [0.69; 1.37]
O’Donnell, 2021 1.38 [0.73; 2.61]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
Ruzhentsova T, 2020 1.11 [0.96; 1.29]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shu, 2020 3.68 [0.18; 75.54]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
Synairgen SG016, 2020 3.15 [1.39; 7.14]
Udwadia, 2020 1.75 [1.10; 2.79]
1.30 [1.13 ; 1.50 ] Abuhasira, 2021, ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, Bennett-Guerrero, 2021, Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Li, 2020, Li, 2021, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, Pouladzadeh, 2021, Ruzhentsova T, 2020, Sekine (PLACOVID), 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Synairgen SG016, 2020, Udwadia, 2020 23 44% 7,178 moderate critical clinical improvement (7-day)detailed results ACTIV-3/TICO LY-CoV555 , 2020 0.85 [0.56; 1.29]
Cao, 2020 2.38 [0.38; 14.70]
Cao, 2020 3.16 [0.62; 16.06]
CAP-China (Wang et al.), 2020 0.99 [0.18; 5.51]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.89 [0.59; 1.35]
COALITION II Covid-19 Brazil (Furtado), 2020 0.94 [0.63; 1.40]
GS-US-540-5773 (Goldman), 2020 1.46 [0.95; 2.23]
GS-US-540-5774, 10 days, 2020 1.03 [0.69; 1.53]
GS-US-540-5774, 5 days, 2020 1.41 [0.94; 2.09]
ITAC, 2022 1.06 [0.77; 1.45]
Kirti, 2021 0.90 [0.77; 1.06]
Li, 2020 0.98 [0.27; 3.58]
Li, 2021 1.83 [0.41; 8.14]
Lou Y, 2020 1.00 [0.05; 18.57]
NCT04523831 (Mahmud), 2020 1.93 [1.27; 2.93]
NCT04542694, 2020 2.10 [1.04; 4.24]
ORCHID, 2020 1.16 [0.84; 1.61]
Ruzhentsova T, 2020 1.50 [1.02; 2.21]
Shashi Bhushan, 2021 1.91 [1.03; 3.53]
Shu, 2020 6.72 [1.50; 30.07]
1.23 [1.05 ; 1.44 ] ACTIV-3/TICO LY-CoV555 , 2020, Cao, 2020, Cao, 2020, CAP-China (Wang et al.), 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, ITAC, 2022, Kirti, 2021, Li, 2020, Li, 2021, Lou Y, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, ORCHID, 2020, Ruzhentsova T, 2020, Shashi Bhushan, 2021, Shu, 2020 20 48% 5,086 moderate critical clinical improvement (time to event analysis only)detailed results Abuhasira, 2021 1.22 [0.70; 2.14]
ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33]
Balcells, 2020 0.91 [0.52; 1.60]
Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
Cao, 2020 1.31 [0.94; 1.83]
Cao, 2020 1.67 [0.84; 3.33]
CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
ConPlas-19, 2020 0.95 [0.60; 1.52]
Darazam, 2021 1.37 [0.88; 2.13]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18]
EMPACTA, 2020 1.15 [0.90; 1.47]
FACCT Trial, 2021 0.85 [0.62; 1.16]
GS-US-540-5773 (Goldman), 2020 0.79 [0.61; 1.02]
GS-US-540-5774, 10 days, 2020 1.16 [0.94; 1.44]
GS-US-540-5774, 5 days, 2020 1.15 [0.93; 1.42]
Gunst JD, 2021 1.14 [0.83; 1.57]
Hung et al., 2020 3.92 [1.66; 9.24]
HYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54]
Li, 2020 1.40 [0.79; 2.49]
Li, 2021 1.76 [1.10; 2.81]
NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49]
ORCHID, 2020 0.97 [0.69; 1.36]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 1.00 [0.76; 1.32]
Rahmani, 2020 3.41 [1.33; 8.73]
Ruzhentsova T, 2020 1.63 [1.14; 2.34]
Shinkai, 2021 1.40 [0.91; 2.15]
Solaymani-Dodaran, 2021 0.94 [0.75; 1.17]
Tang X, 2020 1.04 [0.67; 1.62]
Udwadia, 2020 1.75 [1.10; 2.79]
1.16 [1.08 ; 1.26 ] Abuhasira, 2021, ACTT-2 (Kalil), 2020, Balcells, 2020, Bennett-Guerrero, 2021, Cao, 2020, Cao, 2020, CAP-China (Wang et al.), 2020, ConPlas-19, 2020, Darazam, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, EMPACTA, 2020, FACCT Trial, 2021, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, Hung et al., 2020, HYDRA (Hernandez-Cardenas), 2021, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Li, 2020, Li, 2021, NCT04523831 (Mahmud), 2020, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, PlasmAr, 2020, Rahmani, 2020, Ruzhentsova T, 2020, Shinkai, 2021, Solaymani-Dodaran, 2021, Tang X, 2020, Udwadia, 2020 35 44% 9,011 moderate critical death or ventilationdetailed results ACTT-2 (Kalil), 2020 0.69 [0.50; 0.95]
ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.82 [0.63; 1.07]
BACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81]
Balcells, 2020 0.67 [0.14; 3.26]
CAPE-COVID, 2020 0.71 [0.37; 1.35]
COLCOVID, 2021 0.83 [0.67; 1.02]
CONCOR-1, 2021 1.16 [0.94; 1.43]
ConPlas-19, 2020 0.94 [0.86; 1.02]
CORIMUNO-ANA-1, 2021 0.97 [0.62; 1.52]
CORIMUNO-SARI-1 (non ICU), 2021 1.12 [0.56; 2.22]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31]
DAWN-Plasma, 2021 1.01 [0.64; 1.59]
EMPACTA, 2020 0.56 [0.32; 0.97]
Fragoso-Saavedra (PISCO), 2020 0.46 [0.22; 0.96]
Gonzalez (HCQ), 2020 0.69 [0.22; 2.21]
Gonzalez (IVER), 2020 0.89 [0.30; 2.64]
HYCOVID, 2020 1.12 [0.45; 2.79]
LIVE-AIR (Temesgen), 2021 0.65 [0.43; 0.98]
Menichetti, 2021 0.88 [0.59; 1.32]
NCT04310228-FAVI (Zhao), 2020 3.60 [0.13; 102.66]
ORCHID, 2020 1.13 [0.60; 2.13]
RAPID (Sholzberg), 2021 0.59 [0.34; 1.02]
RECOVERY, 2020 1.14 [1.03; 1.27]
RECOVERY, 2021 0.85 [0.78; 0.93]
RECOVERY, 2022 0.90 [0.81; 0.99]
RECOVERY (AZI, Horby), 2020 0.95 [0.87; 1.03]
RECOVERY (colchicine), 2021 1.02 [0.96; 1.09]
RECOVERY (plasma), 2021 0.99 [0.93; 1.05]
RECOVERY (REGN-COV2), 2021 0.83 [0.75; 0.92]
RECOVERY dexamethasone, 2020 0.92 [0.84; 1.01]
Rosas (REMDACTA), 2021 0.98 [0.72; 1.34]
Rutgers, 2021 0.65 [0.43; 0.99]
SOLIDARITY (interferon), 2020 1.05 [0.90; 1.23]
SOLIDARITY (remdesivir), 2020 0.97 [0.85; 1.10]
SOLIDARITY (WHO study) HCQ, 2020 1.11 [0.87; 1.42]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94]
STOP-COVID (Guimarães), 2021 0.63 [0.41; 0.97]
Synairgen SG016, 2020 0.38 [0.09; 1.63]
Veiga, 2021 1.54 [0.65; 3.63]
0.92 [0.88 ; 0.97 ] ACTT-2 (Kalil), 2020, ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, BACC Bay Tocilizumab Trial, 2020, Balcells, 2020, CAPE-COVID, 2020, COLCOVID, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CORIMUNO-ANA-1, 2021, CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, DAWN-Plasma, 2021, EMPACTA, 2020, Fragoso-Saavedra (PISCO), 2020, Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, HYCOVID, 2020, LIVE-AIR (Temesgen), 2021, Menichetti, 2021, NCT04310228-FAVI (Zhao), 2020, ORCHID, 2020, RAPID (Sholzberg), 2021, RECOVERY, 2020, RECOVERY, 2021, RECOVERY, 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, Rosas (REMDACTA), 2021, Rutgers, 2021, SOLIDARITY (interferon), 2020, SOLIDARITY (remdesivir), 2020, SOLIDARITY (WHO study) HCQ, 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, STOP-COVID (Guimarães), 2021, Synairgen SG016, 2020, Veiga, 2021 39 51% 76,577 moderate critical hospital dischargedetailed results ACTIV-3/TICO LY-CoV555 , 2020 0.97 [0.78; 1.20]
CAPE-COVID, 2020 1.67 [0.87; 3.19]
ConPlas-19, 2020 1.02 [0.82; 1.28]
DAWN-Plasma, 2021 1.06 [0.87; 1.30]
EMPACTA, 2020 1.16 [0.90; 1.49]
FACCT Trial, 2021 0.88 [0.64; 1.21]
Fragoso-Saavedra (PISCO), 2020 1.13 [0.82; 1.55]
Gonzalez (HCQ), 2020 1.38 [0.46; 4.16]
Gonzalez (IVER), 2020 0.71 [0.15; 3.40]
HAHPS, 2020 0.91 [0.54; 1.54]
Huang, 2020 2.00 [1.15; 3.47]
HYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42]
Kirti, 2021 1.20 [0.73; 1.98]
Li T, 2020 10.00 [1.03; 97.50]
MARIPOSA, 2021 0.88 [0.55; 1.40]
Murai, 2020 0.99 [0.71; 1.38]
Rahmani, 2020 3.44 [0.64; 18.49]
RECOVERY, 2020 0.98 [0.91; 1.05]
RECOVERY (Aspirin), 2022 1.06 [1.02; 1.10]
RECOVERY (AZI, Horby), 2020 1.04 [0.98; 1.10]
RECOVERY (colchicine), 2021 0.98 [0.94; 1.03]
RECOVERY (plasma), 2021 0.99 [0.92; 1.07]
RECOVERY (REGN-COV2), 2021 1.19 [1.08; 1.31]
RECOVERY dexamethasone, 2020 1.10 [1.03; 1.17]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.69; 1.00]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.43; 0.92]
Rosas (REMDACTA), 2021 0.97 [0.79; 1.20]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09]
Synairgen SG016, 2020 1.63 [0.61; 4.35]
Udwadia, 2020 1.41 [0.97; 2.03]
University of Minnesota, 2020 0.64 [0.37; 1.11]
1.04 [0.99 ; 1.08 ] ACTIV-3/TICO LY-CoV555 , 2020, CAPE-COVID, 2020, ConPlas-19, 2020, DAWN-Plasma, 2021, EMPACTA, 2020, FACCT Trial, 2021, Fragoso-Saavedra (PISCO), 2020, Gonzalez (HCQ), 2020, Gonzalez (IVER), 2020, HAHPS, 2020, Huang, 2020, HYDRA (Hernandez-Cardenas), 2021, Kirti, 2021, Li T, 2020, MARIPOSA, 2021, Murai, 2020, Rahmani, 2020, RECOVERY, 2020, RECOVERY (Aspirin), 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY (REGN-COV2), 2021, RECOVERY dexamethasone, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, Rosas (REMDACTA), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Synairgen SG016, 2020, Udwadia, 2020, University of Minnesota, 2020 31 52% 66,163 moderate low hospitalizationdetailed results Jagannathan, 2020 1.00 [0.14; 7.34]
University of Minnesota, 2020 1.63 [0.94; 2.85]
1.58 [0.92 ; 2.70 ] Jagannathan, 2020, University of Minnesota, 2020 2 0% 325 moderate not evaluable mechanical ventilationdetailed results Abuhasira, 2021 1.62 [0.41; 6.39]
ACTT-2 (Kalil), 2020 0.64 [0.44; 0.93]
AlQahtani, 2020 0.67 [0.22; 2.02]
Balcells, 2020 2.98 [0.41; 21.61]
CAPE-COVID, 2020 0.95 [0.44; 2.04]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.77 [0.81; 3.87]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.54 [0.70; 3.37]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
COPLA-II trial, 2020 0.58 [0.37; 0.92]
COVACTA (Rosas), 2020 0.67 [0.39; 1.14]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67]
Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67]
Fragoso-Saavedra (PISCO), 2020 0.85 [0.27; 2.62]
Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.70 [0.52; 0.95]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.85 [0.68; 1.06]
Galan, 2021 0.14 [0.03; 0.71]
GRECCO-19, 2020 0.17 [0.02; 1.48]
GS-US-540-5774, 10 days, 2020 0.26 [0.03; 2.30]
GS-US-540-5774, 5 days, 2020 0.13 [0.01; 2.45]
Gunst JD, 2021 2.27 [0.62; 8.26]
Holm K, 2021 0.39 [0.01; 12.68]
I-TECH (Lim), 2022 0.41 [0.13; 1.30]
Jamaati, 2021 1.38 [0.45; 4.20]
Kirti, 2021 0.20 [0.00; 8.69]
Li, 2021 0.52 [0.02; 15.78]
Li T, 2020 0.40 [0.04; 3.90]
Lopes (BRACE CORONA), 2021 1.25 [0.76; 2.06]
Lou Y, 2020 2.11 [0.06; 70.98]
Mahajan, 2021 2.27 [0.39; 13.27]
MARIPOSA, 2021 0.88 [0.37; 2.10]
Metcovid, 2020 1.19 [0.56; 2.49]
Mobarak S (DISCOVER), 2021 1.52 [0.72; 3.19]
Murai, 2020 0.49 [0.21; 1.14]
NCT04397757, 2021 0.41 [0.13; 1.35]
O’Donnell, 2021 1.50 [0.47; 4.82]
PlasmAr, 2020 0.86 [0.39; 1.93]
Rahmani, 2020 0.29 [0.05; 1.56]
Ranjbar, 2021 0.36 [0.13; 0.97]
RAPID (Sholzberg), 2021 0.70 [0.32; 1.54]
RCT-TCZ-COVID-19, 2021 1.36 [0.39; 4.69]
RECOVERY, 2022 0.87 [0.74; 1.02]
RECOVERY (AZI, Horby), 2020 0.92 [0.79; 1.07]
RECOVERY (colchicine), 2021 1.04 [0.93; 1.16]
RECOVERY (plasma), 2021 0.98 [0.88; 1.09]
RECOVERY dexamethasone, 2020 0.77 [0.62; 0.95]
Rutgers, 2021 0.65 [0.35; 1.24]
Sadeghi , 2020 0.37 [0.09; 1.58]
Sakoulas, 2020 0.19 [0.03; 1.11]
SAVE-MORE, 2021 0.47 [0.03; 7.48]
Sekhavati, 2020 0.16 [0.01; 3.19]
Shahbaznejad, 2020 2.24 [0.19; 25.88]
Shu, 2020 0.59 [0.02; 14.04]
Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48]
Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07]
Soin AS (COVINTOC), 2021 1.05 [0.46; 2.38]
Solaymani-Dodaran, 2021 1.62 [0.85; 3.08]
SOLIDARITY (remdesivir), 2020 1.04 [0.87; 1.23]
Tabarsi, 2020 1.49 [0.59; 3.78]
Udwadia, 2020 0.06 [0.01; 0.83]
University of Minnesota, 2020 1.34 [0.66; 2.73]
Yakoot, 2020 0.38 [0.07; 2.08]
0.88 [0.81 ; 0.96 ] Abuhasira, 2021, ACTT-2 (Kalil), 2020, AlQahtani, 2020, Balcells, 2020, CAPE-COVID, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, COPLA-II trial, 2020, COVACTA (Rosas), 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Fragoso-Saavedra (PISCO), 2020, Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, Galan, 2021, GRECCO-19, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, Holm K, 2021, I-TECH (Lim), 2022, Jamaati, 2021, Kirti, 2021, Li, 2021, Li T, 2020, Lopes (BRACE CORONA), 2021, Lou Y, 2020, Mahajan, 2021, MARIPOSA, 2021, Metcovid, 2020, Mobarak S (DISCOVER), 2021, Murai, 2020, NCT04397757, 2021, O’Donnell, 2021, PlasmAr, 2020, Rahmani, 2020, Ranjbar, 2021, RAPID (Sholzberg), 2021, RCT-TCZ-COVID-19, 2021, RECOVERY, 2022, RECOVERY (AZI, Horby), 2020, RECOVERY (colchicine), 2021, RECOVERY (plasma), 2021, RECOVERY dexamethasone, 2020, Rutgers, 2021, Sadeghi , 2020, Sakoulas, 2020, SAVE-MORE, 2021, Sekhavati, 2020, Shahbaznejad, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 2021, Solaymani-Dodaran, 2021, SOLIDARITY (remdesivir), 2020, Tabarsi, 2020, Udwadia, 2020, University of Minnesota, 2020, Yakoot, 2020 61 29% 59,395 moderate critical mechanical ventilation (time to event analysis only)detailed results CP-COVID-19, 2021 0.66 [0.25; 1.72]
DAWN-Plasma, 2021 1.08 [0.65; 1.80]
Fragoso-Saavedra (PISCO), 2020 0.81 [0.27; 2.42]
Gunst JD, 2021 0.69 [0.14; 3.42]
Udwadia, 2020 0.06 [0.01; 0.83]
0.79 [0.47 ; 1.33 ] CP-COVID-19, 2021, DAWN-Plasma, 2021, Fragoso-Saavedra (PISCO), 2020, Gunst JD, 2021, Udwadia, 2020 5 22% 993 moderate serious radiologic improvement (14-day)detailed results Cao, 2020 5.54 [1.01; 30.50]
ELACOI (lopinavir/ritonavir), 2020 0.48 [0.02; 11.28]
ELACOI (Standard of care), 2020 0.18 [0.01; 3.99]
Huang, 2020 1.33 [0.94; 1.88]
Jamaati, 2021 4.89 [1.15; 20.79]
NCT04310228-FAVI (Zhao), 2020 0.32 [0.06; 1.63]
Rashad (CLARI vs SoC), 2021 2.87 [1.56; 5.28]
Rashad A (AZI vs SoC), 2021 1.64 [0.94; 2.88]
Tabarsi, 2020 2.33 [0.45; 12.00]
1.74 [1.09 ; 2.79 ] Cao, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Huang, 2020, Jamaati, 2021, NCT04310228-FAVI (Zhao), 2020, Rashad (CLARI vs SoC), 2021, Rashad A (AZI vs SoC), 2021, Tabarsi, 2020 9 48% 647 moderate not evaluable radiologic improvement (7-day)detailed results ELACOI (lopinavir/ritonavir), 2020 0.10 [0.00; 2.09]
ELACOI (Standard of care), 2020 0.08 [0.00; 1.71]
Huang, 2020 2.40 [0.26; 22.51]
Ren, 2020 19.00 [0.85; 422.73]
0.82 [0.07 ; 9.29 ] ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Huang, 2020, Ren, 2020 4 66% 88 moderate not evaluable viral clearance detailed results AVIFAVIR, 2020 3.89 [1.23; 12.29]
Balcells, 2020 2.66 [0.69; 10.20]
Chaccour, 2020 0.92 [0.77; 1.09]
CP-COVID-19, 2021 1.12 [0.16; 7.84]
Dabbous HM, 2020 1.33 [0.60; 2.93]
ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
ELACOI (Standard of care), 2020 2.80 [0.31; 25.53]
Huang, 2020 1.20 [0.78; 1.85]
Hung et al., 2020 4.37 [1.86; 10.25]
Jagannathan, 2020 0.81 [0.56; 1.18]
Li, 2021 7.68 [0.91; 65.15]
Lou (FAVIPIRAVIR), 2020 0.18 [0.01; 4.75]
NCT04542694, 2020 13.03 [2.96; 57.24]
Pandit, 2021 2.33 [0.55; 9.83]
Raman, 2021 36.42 [10.85; 122.18]
Ravichandran, 2021 1.71 [0.80; 3.64]
Ren, 2020 28.50 [1.27; 640.66]
Ruzhentsova T, 2020 1.28 [0.92; 1.79]
Salman, 2020 1.00 [0.02; 53.89]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
Tang X, 2020 1.78 [1.06; 3.00]
Udwadia, 2020 1.37 [0.94; 1.98]
1.99 [1.45 ; 2.74 ] AVIFAVIR, 2020, Balcells, 2020, Chaccour, 2020, CP-COVID-19, 2021, Dabbous HM, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Huang, 2020, Hung et al., 2020, Jagannathan, 2020, Li, 2021, Lou (FAVIPIRAVIR), 2020, NCT04542694, 2020, Pandit, 2021, Raman, 2021, Ravichandran, 2021, Ren, 2020, Ruzhentsova T, 2020, Salman, 2020, Shashi Bhushan, 2021, Tang X, 2020, Udwadia, 2020 22 76% 1,920 moderate critical viral clearance (time to event analysis only)detailed results Hung et al., 2020 4.37 [1.86; 10.25]
Jagannathan, 2020 0.81 [0.56; 1.18]
Li, 2021 1.74 [1.10; 2.75]
Ruzhentsova T, 2020 1.28 [0.92; 1.79]
Tang X, 2020 1.78 [1.06; 3.00]
Udwadia, 2020 1.37 [0.94; 1.98]
1.48 [1.06 ; 2.06 ] Hung et al., 2020, Jagannathan, 2020, Li, 2021, Ruzhentsova T, 2020, Tang X, 2020, Udwadia, 2020 6 70% 747 moderate serious viral clearance by day 14detailed results AVIFAVIR, 2020 3.08 [0.62; 15.39]
Chen, 2020 1.42 [0.26; 7.76]
CP-COVID-19, 2021 1.51 [0.33; 6.94]
ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
ELACOI (Lopinavir/ritonavir), 2020 1.84 [0.40; 8.38]
ELACOI (Standard of care), 2020 2.80 [0.31; 25.53]
Huang, 2020 1.09 [0.95; 1.26]
Kirenga, 2021 0.95 [0.76; 1.19]
Li, 2021 1.74 [0.71; 4.29]
Li T, 2020 1.00 [0.03; 34.67]
Lou (FAVIPIRAVIR), 2020 0.18 [0.01; 4.75]
Lou Y, 2020 0.12 [0.01; 2.86]
Pandit, 2021 10.23 [1.12; 93.35]
Raman, 2021 36.42 [10.85; 122.18]
Ruzhentsova T, 2020 0.99 [0.93; 1.06]
Shashi Bhushan, 2021 0.00 [0.00; 0.01]
1.01 [0.66 ; 1.55 ] AVIFAVIR, 2020, Chen, 2020, CP-COVID-19, 2021, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Huang, 2020, Kirenga, 2021, Li, 2021, Li T, 2020, Lou (FAVIPIRAVIR), 2020, Lou Y, 2020, Pandit, 2021, Raman, 2021, Ruzhentsova T, 2020, Shashi Bhushan, 2021 16 91% 2,238 moderate low viral clearance by day 7detailed results AVIFAVIR, 2020 3.89 [1.23; 12.29]
Balcells, 2020 2.66 [0.69; 10.20]
Chaccour, 2020 0.92 [0.77; 1.09]
Dabbous HM, 2020 1.33 [0.60; 2.93]
ELACOI (lopinavir/ritonavir), 2020 0.30 [0.05; 1.91]
ELACOI (Lopinavir/ritonavir), 2020 1.08 [0.41; 2.89]
ELACOI (Standard of care), 2020 0.67 [0.10; 4.58]
Huang, 2020 1.20 [0.60; 2.40]
Kirenga, 2021 0.87 [0.65; 1.16]
Kirti, 2021 0.80 [0.43; 1.50]
Li, 2021 2.20 [0.95; 5.10]
Lou Y, 2020 1.50 [0.26; 8.82]
Pandit, 2021 2.33 [0.55; 9.83]
Ravichandran, 2021 1.71 [0.80; 3.64]
Ren, 2020 28.50 [1.27; 640.66]
Ruzhentsova T, 2020 1.05 [0.92; 1.20]
Salman, 2020 1.00 [0.02; 53.89]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
1.21 [0.99 ; 1.48 ] AVIFAVIR, 2020, Balcells, 2020, Chaccour, 2020, Dabbous HM, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Huang, 2020, Kirenga, 2021, Kirti, 2021, Li, 2021, Lou Y, 2020, Pandit, 2021, Ravichandran, 2021, Ren, 2020, Ruzhentsova T, 2020, Salman, 2020, Shashi Bhushan, 2021 18 48% 1,347 moderate critical ICU admissiondetailed results Abd-Elsalam, 2020 0.83 [0.35; 1.95]
Abuhasira, 2021 1.96 [0.51; 7.52]
COL-COVID (Pascual-Figal), 2021 0.47 [0.08; 2.69]
COVACTA (Rosas), 2020 0.48 [0.25; 0.94]
CP-COVID-19, 2021 0.82 [0.35; 1.91]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71]
Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94]
Entrenas (Pilot Calcifediol), 2020 0.03 [0.00; 0.27]
FACCT Trial, 2021 1.42 [0.79; 2.55]
Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021 0.87 [0.69; 1.10]
Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 0.99 [0.56; 1.75]
Galan, 2021 1.42 [0.68; 2.99]
Gunst JD, 2021 0.80 [0.34; 1.90]
I-TECH (Lim), 2022 0.78 [0.27; 2.23]
Khamis, 2020 1.03 [0.35; 3.03]
Kirti, 2021 0.90 [0.30; 2.70]
Libster, 2020 0.33 [0.07; 1.58]
Lopardo, 2021 0.67 [0.35; 1.28]
Lou (FAVIPIRAVIR), 2020 5.43 [0.21; 139.89]
Lou Y, 2020 2.11 [0.06; 70.98]
Murai, 2020 0.71 [0.37; 1.37]
ProPAC-COVID, 2021 1.24 [0.26; 5.80]
Rahmani, 2020 0.37 [0.14; 1.00]
RAPID (Sholzberg), 2021 0.79 [0.48; 1.30]
Rutgers, 2021 0.96 [0.55; 1.68]
Sekhavati, 2020 0.25 [0.05; 1.28]
Soin AS (COVINTOC), 2021 1.33 [0.67; 2.64]
Solaymani-Dodaran, 2021 1.23 [0.70; 2.18]
Tabarsi, 2020 0.56 [0.18; 1.74]
Tang X, 2020 1.00 [0.13; 7.45]
Yakoot, 2020 0.38 [0.07; 2.08]
0.85 [0.73 ; 0.99 ] Abd-Elsalam, 2020, Abuhasira, 2021, COL-COVID (Pascual-Figal), 2021, COVACTA (Rosas), 2020, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Entrenas (Pilot Calcifediol), 2020, FACCT Trial, 2021, Gaitan-Duarte (Rosuvastatin plus colchicine plus emtricitabine/tenofovir), 2021, Gaitan-Duarte (Rosuvastatin plus colchicine), 2021, Galan, 2021, Gunst JD, 2021, I-TECH (Lim), 2022, Khamis, 2020, Kirti, 2021, Libster, 2020, Lopardo, 2021, Lou (FAVIPIRAVIR), 2020, Lou Y, 2020, Murai, 2020, ProPAC-COVID, 2021, Rahmani, 2020, RAPID (Sholzberg), 2021, Rutgers, 2021, Sekhavati, 2020, Soin AS (COVINTOC), 2021, Solaymani-Dodaran, 2021, Tabarsi, 2020, Tang X, 2020, Yakoot, 2020 31 10% 5,180 moderate low Major thrombotic events or deathdetailed results COVID-PACT, 2022 0.56 [0.32; 0.98]
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.04 [0.80; 1.36]
0.80 [0.44 ; 1.46 ] COVID-PACT, 2022, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 2 73% 1,473 moderate not evaluable off oxygenationdetailed results HYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51]
0.98 [0.64 ; 1.51 ] HYDRA (Hernandez-Cardenas), 2021 1 0% 214 NA not evaluable recoverydetailed results Abdulamir, 2021 1.00 [0.20; 5.12]
ACTIV-3 (BRII-196 and BRII-198), 2021 1.08 [0.88; 1.32]
ACTIV-3/ TICO (sotrovimab), 2021 1.12 [0.91; 1.37]
ACTIV-3/TICO LY-CoV555 , 2020 1.06 [0.77; 1.46]
COV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20]
Crippa (CANDIDATE), 2021 0.54 [0.15; 1.94]
GS-US-540-5773 (Goldman), 2020 0.81 [0.64; 1.03]
GS-US-540-5774, 10 days, 2020 1.11 [0.90; 1.37]
GS-US-540-5774, 5 days, 2020 1.18 [0.96; 1.45]
Gunst JD, 2021 1.18 [0.87; 1.61]
Lanzoni, 2021 3.46 [1.05; 11.35]
Mobarak S (DISCOVER), 2021 0.97 [0.89; 1.05]
Synairgen SG016, 2020 2.19 [1.03; 4.67]
Talaschian, 2021 0.64 [0.14; 2.92]
Yakoot, 2020 1.60 [1.00; 2.55]
1.09 [0.98 ; 1.21 ] Abdulamir, 2021, ACTIV-3 (BRII-196 and BRII-198), 2021, ACTIV-3/ TICO (sotrovimab), 2021, ACTIV-3/TICO LY-CoV555 , 2020, COV-BARRIER (critically ill), 2022, Crippa (CANDIDATE), 2021, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, Lanzoni, 2021, Mobarak S (DISCOVER), 2021, Synairgen SG016, 2020, Talaschian, 2021, Yakoot, 2020 15 40% 4,104 moderate critical severe COVID-19 occurrencedetailed results ELACOI (Lopinavir/ritonavir), 2020 0.30 [0.07; 1.27]
0.30 [0.07 ; 1.27 ] ELACOI (Lopinavir/ritonavir), 2020 1 0% 69 NA not evaluable AE leading to drug discontinuationdetailed results CAP-China (Wang et al.), 2020 2.43 [0.79; 7.45]
2.43 [0.79 ; 7.45 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable cardiac arrestdetailed results SOLIDARITY (WHO study) HCQ, 2020 1.92 [0.35; 10.49]
1.92 [0.35 ; 10.49 ] SOLIDARITY (WHO study) HCQ, 2020 1 0% 1,853 NA not evaluable composite safety outcome detailed results ACTIV-3/TICO LY-CoV555 , 2020 1.56 [0.78; 3.11]
1.56 [0.78 ; 3.11 ] ACTIV-3/TICO LY-CoV555 , 2020 1 0% 314 NA not evaluable related AE (TRAE)detailed results Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93]
1.26 [0.14 ; 11.07 ] Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 2 0% 25 moderate not evaluable related SAE (TRSAE)detailed results COALITION II Covid-19 Brazil (Furtado), 2020 1.24 [0.50; 3.11]
Wang, 2020 2.04 [0.07; 63.93]
1.29 [0.53 ; 3.11 ] COALITION II Covid-19 Brazil (Furtado), 2020, Wang, 2020 2 0% 487 moderate not evaluable serious adverse eventsdetailed results BACC Bay Tocilizumab Trial, 2020 1.21 [0.58; 2.53]
Balcells, 2020 4.54 [0.20; 105.23]
CAN-COVID, 2020 0.73 [0.45; 1.19]
Cao, 2020 0.52 [0.27; 1.01]
Cao, 2020 0.11 [0.01; 2.21]
CAP-China (Wang et al.), 2020 0.64 [0.33; 1.23]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.87 [0.36; 9.75]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.02 [0.20; 5.10]
COALITION II Covid-19 Brazil (Furtado), 2020 1.20 [0.82; 1.77]
CODEX (Tomazini), 2020 0.53 [0.17; 1.62]
COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41]
CONCOR-1, 2021 1.27 [1.02; 1.58]
ConPlas-19, 2020 0.89 [0.43; 1.86]
COVACTA (Rosas), 2020 0.81 [0.54; 1.22]
Dongsheng Wang, 2020 0.91 [0.02; 47.31]
GS-US-540-5774, 10 days, 2020 0.55 [0.25; 1.23]
GS-US-540-5774, 5 days, 2020 0.50 [0.22; 1.14]
Gunst JD, 2021 1.84 [0.79; 4.30]
Hung et al., 2020 0.23 [0.01; 7.12]
ITAC, 2022 0.98 [0.66; 1.46]
Jagannathan, 2020 1.00 [0.14; 7.34]
Krolewiecki, 2020 1.00 [0.03; 31.59]
Lanzoni, 2021 0.10 [0.01; 0.69]
Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12]
Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51]
Lou Y, 2020 2.25 [0.38; 13.47]
Murai, 2020 0.99 [0.02; 50.39]
NCT04523831 (Mahmud), 2020 3.97 [0.18; 88.58]
NCT04542694, 2020 6.15 [0.30; 124.49]
NIH NIAID ACTT-1, 2020 0.72 [0.54; 0.96]
ORCHID, 2020 1.26 [0.56; 2.84]
O’Donnell, 2021 0.64 [0.35; 1.17]
Pandit, 2021 0.95 [0.02; 50.33]
PlasmAr, 2020 1.40 [0.78; 2.51]
Raman, 2021 0.49 [0.02; 15.10]
REMAP-CAP (lopinavir/ritonavir only), 2020 1.57 [0.70; 3.49]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.97 [0.22; 4.33]
REMAP-CAP (plasma), 2021 2.28 [1.17; 4.46]
Ren, 2020 1.00 [0.02; 55.80]
Rosas (REMDACTA), 2021 0.83 [0.59; 1.18]
Ruzhentsova T, 2020 2.06 [0.09; 46.40]
Sadeghi , 2020 1.00 [0.02; 51.94]
Sekine (PLACOVID), 2021 1.14 [0.88; 1.48]
Shi, 2020 1.08 [0.04; 32.96]
Shinkai, 2021 2.80 [0.14; 56.95]
Soin AS (COVINTOC), 2021 0.97 [0.44; 2.13]
Talaschian, 2021 7.93 [0.37; 171.38]
Udwadia, 2020 1.03 [0.02; 52.48]
Veiga, 2021 1.66 [0.60; 4.59]
Yakoot, 2020 1.02 [0.02; 52.72]
0.99 [0.88 ; 1.11 ] BACC Bay Tocilizumab Trial, 2020, Balcells, 2020, CAN-COVID, 2020, Cao, 2020, Cao, 2020, CAP-China (Wang et al.), 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, CODEX (Tomazini), 2020, COL-COVID (Pascual-Figal), 2021, CONCOR-1, 2021, ConPlas-19, 2020, COVACTA (Rosas), 2020, Dongsheng Wang, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, Hung et al., 2020, ITAC, 2022, Jagannathan, 2020, Krolewiecki, 2020, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Lou Y, 2020, Murai, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, NIH NIAID ACTT-1, 2020, ORCHID, 2020, O’Donnell, 2021, Pandit, 2021, PlasmAr, 2020, Raman, 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (plasma), 2021, Ren, 2020, Rosas (REMDACTA), 2021, Ruzhentsova T, 2020, Sadeghi , 2020, Sekine (PLACOVID), 2021, Shi, 2020, Shinkai, 2021, Soin AS (COVINTOC), 2021, Talaschian, 2021, Udwadia, 2020, Veiga, 2021, Yakoot, 2020 50 16% 15,000 moderate low superinfectiondetailed results ACTT-2 (Kalil), 2020 0.50 [0.32; 0.79]
CAPE-COVID, 2020 0.81 [0.49; 1.34]
Metcovid, 2020 0.98 [0.65; 1.47]
Rahmani, 2020 0.18 [0.02; 1.59]
0.70 [0.46 ; 1.07 ] ACTT-2 (Kalil), 2020, CAPE-COVID, 2020, Metcovid, 2020, Rahmani, 2020 4 53% 1,641 low not evaluable acute kidney injury detailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.18 [0.44; 3.18]
1.18 [0.44 ; 3.18 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 345 NA not evaluable adverse eventsdetailed results Cao, 2020 1.60 [0.38; 6.81]
Chaccour, 2020 1.00 [0.20; 5.07]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.22 [1.43; 3.44]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.74 [1.10; 2.75]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.21 [0.82; 1.78]
COL-COVID (Pascual-Figal), 2021 1.72 [0.73; 4.08]
COVACTA (Rosas), 2020 0.87 [0.52; 1.45]
Dongsheng Wang, 2020 9.64 [2.76; 33.75]
GS-US-540-5774, 10 days, 2020 1.63 [1.09; 2.42]
GS-US-540-5774, 5 days, 2020 1.21 [0.82; 1.80]
Gunst JD, 2021 0.80 [0.43; 1.51]
Huang, 2020 1.80 [0.14; 23.37]
Jagannathan, 2020 1.33 [0.63; 2.78]
Kirenga, 2021 1.13 [0.50; 2.58]
Krolewiecki, 2020 1.53 [0.42; 5.58]
Lanzoni, 2021 0.18 [0.02; 1.95]
Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69]
Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27]
Murai, 2020 1.99 [0.07; 59.94]
NCT04310228-FAVI (Zhao), 2020 0.60 [0.05; 6.80]
NCT04523831 (Mahmud), 2020 18.57 [1.07; 322.77]
NCT04542694, 2020 1.00 [0.54; 1.85]
ORCHID, 2020 1.42 [0.87; 2.34]
Pandit, 2021 1.68 [0.47; 5.97]
Raman, 2021 1.36 [0.56; 3.30]
Ravichandran, 2021 1.04 [0.02; 52.86]
RECOVERY, 2020 1.36 [0.98; 1.90]
Ren, 2020 0.12 [0.01; 2.86]
Rosas (REMDACTA), 2021 1.32 [0.92; 1.89]
Ruzhentsova T, 2020 1.90 [0.96; 3.80]
Sakoulas, 2020 1.00 [0.02; 53.46]
Sekine (PLACOVID), 2021 1.08 [0.85; 1.38]
Shi, 2020 0.88 [0.38; 2.03]
Shinkai, 2021 19.54 [7.77; 49.11]
Shu, 2020 2.48 [0.05; 132.54]
Singh (TD-0903 1mg), 2021 0.45 [0.01; 16.71]
Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01]
Soin AS (COVINTOC), 2021 1.50 [0.78; 2.87]
TEACH, 2020 1.16 [0.55; 2.42]
Udwadia, 2020 6.36 [2.43; 16.65]
Veiga, 2021 1.65 [0.81; 3.37]
Wang, 2020 3.57 [0.93; 13.72]
1.47 [1.23 ; 1.75 ] Cao, 2020, Chaccour, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, COVACTA (Rosas), 2020, Dongsheng Wang, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Gunst JD, 2021, Huang, 2020, Jagannathan, 2020, Kirenga, 2021, Krolewiecki, 2020, Lanzoni, 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Murai, 2020, NCT04310228-FAVI (Zhao), 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, ORCHID, 2020, Pandit, 2021, Raman, 2021, Ravichandran, 2021, RECOVERY, 2020, Ren, 2020, Rosas (REMDACTA), 2021, Ruzhentsova T, 2020, Sakoulas, 2020, Sekine (PLACOVID), 2021, Shi, 2020, Shinkai, 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Soin AS (COVINTOC), 2021, TEACH, 2020, Udwadia, 2020, Veiga, 2021, Wang, 2020 42 54% 12,069 moderate low arrhythmiadetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.24 [0.23; 21.69]
RECOVERY (AZI, Horby), 2020 0.90 [0.71; 1.15]
Sekhavati, 2020 0.98 [0.02; 50.38]
0.91 [0.72 ; 1.15 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, RECOVERY (AZI, Horby), 2020, Sekhavati, 2020 3 0% 8,290 moderate not evaluable deep vein thrombosisdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
NIH NIAID ACTT-1, 2020 0.64 [0.23; 1.81]
0.62 [0.23 ; 1.64 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable elevated liver enzymesdetailed results CAP-China (Wang et al.), 2020 0.36 [0.13; 1.01]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 3.48 [1.40; 8.64]
NIH NIAID ACTT-1, 2020 0.67 [0.38; 1.18]
0.95 [0.29 ; 3.10 ] CAP-China (Wang et al.), 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, NIH NIAID ACTT-1, 2020 3 84% 1,712 moderate not evaluable hyperbilirubinemiadetailed results CAP-China (Wang et al.), 2020 1.09 [0.42; 2.79]
NIH NIAID ACTT-1, 2020 0.84 [0.30; 2.34]
0.97 [0.48 ; 1.93 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 low not evaluable long QTdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 9.79 [1.27; 75.50]
COALITION II Covid-19 Brazil (Furtado), 2020 0.90 [0.56; 1.43]
2.39 [0.24 ; 23.87 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION II Covid-19 Brazil (Furtado), 2020 2 80% 613 moderate not evaluable Major bleedingdetailed results ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.80 [0.88; 3.67]
COALIZAO ACTION, 2021 2.50 [0.78; 8.06]
COVID-PACT, 2022 3.86 [0.44; 34.07]
INSPIRATION, 2021 1.83 [0.53; 6.34]
REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.48 [0.74; 2.98]
1.80 [1.18 ; 2.75 ] ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, COALIZAO ACTION, 2021, COVID-PACT, 2022, INSPIRATION, 2021, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 5 0% 4,876 moderate serious pulmonary embolismdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
NIH NIAID ACTT-1, 2020 0.96 [0.19; 4.80]
0.82 [0.20 ; 3.29 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable renal impairmentdetailed results CAP-China (Wang et al.), 2020 1.01 [0.03; 30.33]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.35 [0.47; 3.86]
COALITION II Covid-19 Brazil (Furtado), 2020 1.44 [0.99; 2.11]
NIH NIAID ACTT-1, 2020 1.02 [0.64; 1.61]
1.26 [0.95 ; 1.67 ] CAP-China (Wang et al.), 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, NIH NIAID ACTT-1, 2020 4 0% 2,066 moderate not evaluable serious adverse events (SAE), anydetailed results GS-US-540-5773 (Goldman), 2020 0.50 [0.32; 0.79]
0.50 [0.32 ; 0.79 ] GS-US-540-5773 (Goldman), 2020 1 0% 397 NA not evaluable Thromboembolic eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.89 [0.31; 2.55]
COALIZAO ACTION, 2021 0.73 [0.41; 1.29]
INSPIRATION, 2021 1.07 [0.76; 1.49]
0.96 [0.73 ; 1.27 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALIZAO ACTION, 2021, INSPIRATION, 2021 3 0% 1,521 moderate not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-26 19:36 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290